复方阿嗪米特肠溶片联合莫沙必利治疗慢传输型便秘295例临床研究  

Compound azimtamide entieric-coated tablets combined with mosapride for slow transmissive constipation: 295 cases

作　　者：侯立新 李爽 黄兰蔚 崔永康 梅灿勇 

机构地区：[1]曙光医院宝山分院,上海宝山201900

出　　处：《中南药学》2014年第1期80-82,共3页Central South Pharmacy

摘　　要：目的观察复方阿嗪米特联合莫沙必利治疗慢传输型便秘(简称STC)的疗效。方法 295例患者随机分为3组,治疗组113例给予复方阿嗪米特联合莫沙必利治疗,对照A组98例给予复方阿嗪米特治疗,对照B组84例给予莫沙必利治疗。3组均治疗3个月后观察疗效。结果总有效率治疗组为89.4%,对照A组为66.3%,对照B组为70.2%,治疗组优于对照A、B组(P均<0.05),两对照A、B组间差异无显著性意义(P>0.05)。结论与莫沙必利联合治疗慢传输型便秘的疗效较单纯复方阿嗪米特或莫沙必利治疗更为显著,并能显著缓解腹胀等慢传输型便秘的相关症状,值得临床推广及进一步观察研究。Objective To investigate and study the curative effect of compound azimtamide entieric-coated tablets com- bined with mosapride for slow transmissive constipation. Methods A total of 295 patients were randomly divided into 3 groups： 113 patients in treatment group were treated with compound azimtamide entieric-coated tablets combined with mosapfide, 98 in control group A were treated with compound azimtamide entieric-coated tablets, and 84 in conrol group B were treated with mosapride. The 3 groups were treated for 3 months, and the curative effects were observed. Results The total effective rate were 89.4% in the treatment group, 66.3% in the control group A, and 70.2% in the control group B with significant difference （P ~ 0.05）. Conclusion The curative effect of compound azimtamide entieric-coated tablets combined with mosapride for slow transit constipation was more significant than at of compound azimtamide entieric-coated tablets and mosapride used alone. The treatment can significantly ease symptoms such as abdominal distension in slow transmissive constipation. It is worthy of clinical promotion and further research.

关 键 词：慢传输型便秘 复方阿嗪米特 莫沙必利 

分 类 号：R969.4[医药卫生—药理学]